{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=124",
    "query": {
      "condition": "Skin Disorders",
      "page": 124
    },
    "page_size": 10
  },
  "pagination": {
    "page": 124,
    "page_size": 10,
    "total_count": 16155,
    "total_pages": 1616,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=125&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Disorders&page=123&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T22:46:45.897Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02165605",
      "title": "HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "HylaCare",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 99 Years · Female only"
      },
      "enrollment_count": 28,
      "start_date": "2012-08",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2020-10-22",
      "last_synced_at": "2026-11-17T22:46:45.897Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02165605"
    },
    {
      "nct_id": "NCT06614894",
      "title": "An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Sanfilippo Syndrome",
        "MPS3"
      ],
      "interventions": [
        {
          "name": "Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ozlem Goker-Alpan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 10,
      "start_date": "2024-12-01",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-20",
      "last_synced_at": "2026-11-17T22:46:45.897Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06614894"
    },
    {
      "nct_id": "NCT06090266",
      "title": "A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Tumor, Solid",
        "Malignant Neoplasm",
        "Metastatic Cancer",
        "Advanced Solid Tumor",
        "Cutaneous Melanoma",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "OR502",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoResponse, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 168,
      "start_date": "2023-10-24",
      "completion_date": "2027-02-01",
      "has_results": false,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-11-17T22:46:45.897Z",
      "location_count": 4,
      "location_summary": "Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Irving",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06090266"
    },
    {
      "nct_id": "NCT07223515",
      "title": "HEAL-4: Real-World Effectiveness of 4 Amniotic Allografts Adjunctive to Standard Care in DFU, VLU, and PU",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Foot Ulcer (DFU)",
        "Venous Leg Ulcers (VLUs)",
        "Pressure Ulcers, Bedsores, Decubitus Ulcer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Dynamic Medical Services dba Acesso Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2025-10-24",
      "completion_date": "2025-11",
      "has_results": false,
      "last_update_posted_date": "2025-11-03",
      "last_synced_at": "2026-11-17T22:46:45.897Z",
      "location_count": 2,
      "location_summary": "Novi, Michigan • Murfreesboro, Tennessee",
      "locations": [
        {
          "city": "Novi",
          "state": "Michigan"
        },
        {
          "city": "Murfreesboro",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07223515"
    },
    {
      "nct_id": "NCT06952517",
      "title": "Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Papular-pustular Rosacea",
        "Papulopustular Rosacea (PPR)",
        "Papulopustular Rosacea"
      ],
      "interventions": [
        {
          "name": "Clascoterone Cream 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Narrows Institute for Biomedical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-03-14",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-11-17T22:46:45.897Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06952517"
    },
    {
      "nct_id": "NCT00039325",
      "title": "Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "dendritic cell-MART-1 peptide vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2002-03",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2020-08-03",
      "last_synced_at": "2026-11-17T22:46:45.897Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00039325"
    },
    {
      "nct_id": "NCT02807597",
      "title": "Real-time Intraoperative Breast Cancer Visualization for Margin Assessment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Cancer of the Breast"
      ],
      "interventions": [
        {
          "name": "LS301",
          "type": "DRUG"
        },
        {
          "name": "Cancer Vision Goggles and standard fluorescence imaging systems",
          "type": "DEVICE"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Samuel Achilefu",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-02-18",
      "completion_date": "2022-01-27",
      "has_results": true,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-11-17T22:46:45.897Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02807597"
    },
    {
      "nct_id": "NCT01304797",
      "title": "Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "MM-302 Monotherapy",
          "type": "DRUG"
        },
        {
          "name": "MM-302 in combination with trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "MM-302 in combination with trastuzumab q3w",
          "type": "DRUG"
        },
        {
          "name": "MM-302 in combination with trastuzumab and cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merrimack Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2011-03",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-06",
      "last_synced_at": "2026-11-17T22:46:45.897Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01304797"
    },
    {
      "nct_id": "NCT01694810",
      "title": "Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "2% NVN1000 Topical Gel",
          "type": "DRUG"
        },
        {
          "name": "4% NVN1000 Topical Gel",
          "type": "DRUG"
        },
        {
          "name": "8% NVN1000 Topical Gel",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Topical Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novan, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2012-09",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2020-01-30",
      "last_synced_at": "2026-11-17T22:46:45.897Z",
      "location_count": 1,
      "location_summary": "Broomall, Pennsylvania",
      "locations": [
        {
          "city": "Broomall",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01694810"
    },
    {
      "nct_id": "NCT05020860",
      "title": "Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Neoplasm",
        "Breast Cancer Female",
        "Breast Cancer Invasive",
        "Breast Cancer Stage II",
        "Breast Cancer Stage III",
        "Triple Negative Breast Cancer",
        "Hormone Receptor-positive Breast Cancer",
        "HER2-positive Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "Estrogen Receptor-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab/Trastuzumab/Hyaluronidase-zzxf",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor Breast Care Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2023-04-18",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2025-02-27",
      "last_synced_at": "2026-11-17T22:46:45.897Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05020860"
    }
  ]
}